CND Life Sciences Announces NIH Grant to Study the Risk of Parkinson’s Disease in Patients with Essential Tremor

SCOTTSDALE, AZ, October 22, 2025 – CND Life Sciences (CND), a medical technology company pioneering the development of cutaneous neurodiagnostic tests and associated biomarker services, today announced that it has been awarded a $3 million grant from the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program to determine if the presence of the protein phosphorylated alpha-synuclein (P-SYN) in patients with essential tremor (ET) predicts the likelihood of developing Parkinson’s disease (PD). The company’s Syn-One Test® will be studied as a predictive tool to help assess which patients may be at risk for developing PD. Outcomes from the “Syn-T Study” could have major implications for the treatment and management of people with ET in the future.Continue reading

ASU’s new School of Medicine receives preliminary accreditation, gift and new name

PHOENIX, AZ —  The opening of Arizona State University’s new medical school took a giant leap forward today with two important pieces of news that will accelerate activity as the school begins to prepare for its first class in August 2026.

ASU leaders announced that the school, the flagship of the university’s ASU Health system, received preliminary accreditation from the Liaison Committee on Medical Education (LCME), enabling the school to begin recruiting its first class of students. In addition, the university received a nine-figure gift, the second largest in university history, to establish and operate the new school, which now will be known as the John Shufeldt School of Medicine and Medical Engineering.Continue reading